A fundamental understanding of many biological processes in humans has stemmed from experimental studies in animal models, particularly in rodents. Using these models, key aspects of the development and regulation of the haematopoietic and immune systems have been elucidated at the cellular and molecular levels. However, many aspects of mammalian biological systems, particularly their immune systems, are species specific. Moreover, rodents are refractory to certain human-specific infectious agents, and many of the new therapeutic and immunomodulatory reagents that have been developed are human specific.
A fundamental understanding of many biological processes in humans has stemmed from experimental studies in animal models, particularly in rodents. Using these models, key aspects of the development and regulation of the haematopoietic and immune systems have been elucidated at the cellular and molecular levels. However, many aspects of mammalian biological systems, particularly their immune systems, are species specific. Moreover, rodents are refractory to certain human-specific infectious agents, and many of the new therapeutic and immunomodulatory reagents that have been developed are human specific.
For many years, investigators have relied on chimpanzees to bridge the gap between rodent models and humans. However, the use of chimpanzees for biomedical research has been banned in Europe, and a recent directive from the US National Institutes of Health (NIH) has stopped the funding for new research on chimpanzees in the United States (see the 15 December 2011 press release on the NIH website). Based on these restrictions it is unclear whether experimentation in chimpanzees will be a feasible approach in the future for moving discoveries made in rodents through the preclinical phase to human trials.
Therefore, to address the limitations of translating discoveries in rodents into clinical applications, sophisticated small-animal models that more closely recapitulate human biological systems, such as 'humanized' mice, are more acutely required. We define humanized mice in this Review as immunodeficient mice that have been engrafted with human primary haematopoietic cells and tissues that generate a functional human immune system. We 1 and others 2, 3 have reviewed the history of humanized mice previously, and therefore it is not discussed here. There has been a rapid growth in the use of humanized mice that emanated from breakthroughs following the development of immunodeficient mice with a mutation in the interleukin-2 (IL-2) receptor γ-chain locus (Il2rg; also known as γ c and CD132) in the mid-2000s [4] [5] [6] . The targeted mutation of Il2rg leads to severe impairments in B and T cell development and function, and completely prevents natural killer (NK) cell development. In addition, this mutation affects the development of lymph node anlagen, resulting in poor lymph node development and organization. The focus of this Review is on the progress in the generation and use of new immune cell-or tissue-engrafted humanized mouse models that has occurred over the past few years, the limitations present in the earlier models that have recently been overcome, the challenges yet to be conquered and the promise that humanized mice provide for the future of biomedical research.
Model systems and technologies
To understand the progress, promise and remaining challenges in the use of humanized mice, it is important to recognize the variety and complexity of the model systems being used in a particular study to appropriately interpret the results. Multiple strains of immunodeficient mice with a mutant Il2rg gene have been developed (TABLE 1) , and these strains are quite diverse.
Prkdc scid (Often abbreviated as scid).
A mutant allele that causes a defect in double-strand DNA break repair that prevents B cell receptor and T cell receptor recombination. Mice with this mutation lack functional B and T cells.
Furthermore, the nomenclature surrounding the various strains and models is complex. Any one specific model will not be optimal for addressing the myriad of questions that might be considered, and it is important not only to choose the appropriate model system for the specific question at hand, but also to be innovative in formulating questions and experimental designs to provide valid data that can be properly interpreted using the individual models.
There are three main platforms of mouse strains that are used: NOD. Cg 
Il2rg
tm1Flv stocks of mice (BRG mice) (TABLE 1) . Although the acronym BRG is commonly used to refer to the BALB/c-Rag1
−/− or BALB/c-Rag2
strains that also contain the IL2rg null mutation, it is also a commonly used acronym for mice of a mixed BALB/c and 129 background expressing the Rag2 −/− and Il2rg null mutations (also known as C;129RG mice). Several of the strains of NSG mice and BRG mice are available from The Jackson Laboratory, whereas NOG mice are available from Taconic. The derivation and unique characteristics of each of the immunodeficient mouse models derived from immunodeficient Il2rg null mice have been reviewed in detail 1 . Recent evidence shows that these mouse models differ in their ability to support the engraftment of functional human immune systems. For example, NSG mice and NOD.Cg-Rag1 
tm1Wjl (NRG) mice support higher levels of human haematopoietic stem cell (HSC) engraftment and T cell development than do BRG mice 7 , and NSG mice support higher levels of human HSC engraftment in bone marrow than do NOG mice 8 . Therefore, the choice of the specific mouse model will affect the engraftment levels of the transplanted human haematopoietic and immune systems, the types of cells that can be successfully engrafted, and the functional capabilities of specific immune cells.
There are four different technological approaches for the engraftment of a functional human immune system in these immunodeficient mouse models, each with distinct advantages and caveats (FIG. 1; TABLE 2) . Depending on the question, the investigator will need to choose the appropriate human immune system-engrafted mouse for their studies.
Overcoming limitations in humanized mice
There were previously several major limitations inherent in humanized mice. These were due, in part, to differences between mice and humans in the growth factors and cytokines required for haematopoietic and immune system development (FIG. 2) , and to the presence of mouse MHC molecules rather than human HLA molecules (reviewed in REF. 1). Additional limitations included deficiencies in the development of lymph nodes, poorly organized lymphoid architecture and impaired affinity maturation and class-switching of antibodies following immunization in the humanized mice 1 . In addition, the species specificity of homing molecules may impede the appropriate trafficking of human immune cells in these mice. Finally, the remaining mouse innate immune system in the humanized mouse models represented a continuing impediment to human cell engraftment and the investigation of human immune function 1 . 
Lentiviral vectors
Vectors that are based on slowly replicating retroviruses. They have a more complex genomic structure than oncoretroviruses (which require cell division for stable integration into the genome of a cell), and they express several accessory proteins in addition to Gag, Pol and Env. The main advantage of using these vectors for gene therapy is their relatively high efficiency of stably transducing quiescent cells.
The expression of human transgenes and the targeted inactivation of mouse genes encoding factors that control the development and function of the innate immune system have recently addressed many of these limitations, resulting in enhanced human immune system function in humanized mice. The technological approaches for developing these 'next-generation' immunodeficient Il2rg null mice are quite diverse, and the levels of functional engraftment of human immune systems differ depending on the recipient mouse strain and the technology used.
Technologies to deliver human species-specific factors into mice to enhance human haematopoiesis and immune system development and function are also diverse. The simplest approach is to inject the needed factors as recombinant proteins (reviewed in REF. 9 ). Other technologies include the transduction of human HSCs with genes encoding factors such as mouse CD47 (REF. 10 ), which is a 'don't eat me' signal that regulates the phagocytic uptake of cells, and the delivery into mice of plasmid DNA encoding human cytokines by hydrodynamic tail vein injection 11 . In addition, lentiviral vectors have been used to deliver human IL7 into BRG mice, promoting the homeostatic proliferation of both adoptively transferred and endogenously generated human T cells 12 .
As described below, three main genetic engineering technologies have been adopted: transgenic expression of cDNA constructs driven by tissue-specific or ubiquitous promoters; transgenic expression of bacterial artificial chromosomes (BACs); and knock-in technology.
New tools. Strains of transgenic immunodeficient Il2rg null mice have been developed using cDNA constructs expressing human genes under the control of host tissuespecific or ubiquitous promoters. However, this approach often leads to transgene expression of the human gene at non-physiological levels or without temporal controls, leading to adverse effects on the development and function of the human immune system in humanized mice. A second approach is the use of human-gene-containing BACs, which often incorporate crucial regulatory elements for gene expression. The use of BACs to create transgenic mice facilitates gene expression at physiological levels, when appropriate during development and when functionally needed. Using these transgenic approaches, the homologous mouse gene is left intact, and therefore both the mouse and human gene of interest are expressed. A third approach is to use knock-in technology whereby the mouse gene is replaced by the corresponding human gene, resulting in the expression of the human gene product in the absence of the mouse gene product. This strategy has been successfully used for multiple genes in BRG mice owing to the availability of embryonic stem cells of the C;129RG strain 3 . These embryonic stem cells can also be used to develop knockout mice in which a targeted mouse gene is specifically inactivated. The development of knock-in and knockout mice on the non-obese diabetic (NOD) background was previously hindered by the lack of available NOD embryonic stem cells, but this limitation has recently been overcome by the generation of embryonic stem cells based on the NOD strain 13 and the NSG strain (see the ES cell lines available on the Jackson Laboratory website). This will result in the development of knock-in and knockout NSG and NRG mice.
Additional emerging technologies that can alter the genome of mice have been described, including zinc-finger nuclease (ZFN) technology and transcription activatorlike effector nuclease (TALEN) technology. ZFNs are engineered DNA-binding proteins that cause doublestranded DNA breaks at specific locations and thus enable targeted editing of the genome 14 . TALEN technology uses transcription activator-like effectors, which are secreted by plant bacteria and can be designed to bind to specific DNA sequences 15 . ZFN and TALEN technologies can be applied directly in embryos and thus can be used for the development of new strains with increasing genetic complexity that cannot easily be generated using traditional breeding crosses. Although the use of ZFN and TALEN technologies has not yet been reported in the field of humanized mice, these technologies are likely to make an important impact on future humanized mouse model development.
New models. Many genetically modified strains of immunodeficient Il2rg null mice are now available for the study of human immunobiology (TABLE 3) , and it is likely that many new stocks will soon be available. 
Bacterial artificial chromosomes
(BACs). Cloning vectors derived from single-copy F-plasmids of Escherichia coli that carry the F replication and partitioning systems that ensure low copy number and the faithful segregation of plasmid DNA into daughter cells. Large genomic fragments can be cloned into such vectors and they are faithfully replicated, which makes BACs useful for constructing genomic libraries.
Using knock-in technology, three new strains of BRG mice expressing human haematopoietic growth factors that are important in myeloid cell development have been developed 3 . As expected, each human growth factor enhanced the development of the human cell lineage targeted by that specific factor. For example, transgenic expression of macrophage colony-stimulating factor (M-CSF; encoded by CSF1) increased the frequencies of human monocytes and macrophages following human HSC engraftment and enhanced the production of human pro-inflammatory cytokines following challenge with the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide 16 . However, adverse events were also observed. For example, in the thrombopoietin (THPO) knock-in strain, myelopoiesis and HSC self-renewal were increased, but thrombocytopenia also developed 17 . Although human THPO can support murine thrombo cytopoiesis, the levels of human THPO that were expressed in the mouse were ~10-fold lower than the normal levels of mouse THPO. This led to decreased numbers of mouse platelets, and -because only very low levels of human platelets circulate in the blood of humanized mice -thrombocytopenia developed. In knock-in mice expressing human IL-3 and granulocyte-macrophage colonystimulating factor (GM-CSF; encoded by CSF2), human HSC engraftment resulted in enhanced development of human alveolar macrophages, but non-engrafted mice developed pulmonary alveolar proteinosis caused by the absence of mouse GM-CSF 18 . Transgenic expression of three haematopoietic growth factors (namely IL-3, GM-CSF and stem cell factor (SCF; also known as KIT ligand)) under the control of a ubiquitous promoter led to increased frequencies of human myeloid cells in the bone marrow of NSG mice engrafted with human HSCs 19 . However, earlier studies with these co-integrated transgenes showed that GM-CSF-mediated HSC mobilization resulted in reduced frequencies of human HSCs in the bone marrow compared with non-transgenic NOD.Cg-Prkdc scid (NOD-scid) mice 20 . Increased levels of CD4 + FOXP3 + T cells in the peripheral tissues were also apparent 
Knock-in technology
The introduction of a transgene into a precise location in the genome, rather than a random integration site. Knocking-in uses the same technique of homologous recombination as a knockout strategy, but the targeting vector is designed to allow expression of the introduced transgene under the control of the regulatory elements of the targeted gene.
Thrombocytopenia
A reduced number of circulating platelets, owing either to the failure of production from bone-marrow megakaryocytes or to increased clearance from the circulation, predominantly in the spleen.
following HSC engraftment in the triple-transgenic NSG mice, suggesting that non-physiological exposure to cytokines during T cell development can alter the cell population that is generated 19 . This deficiency might be overcome using the knock-in approach, which would be expected to result in physiological levels of cytokines.
By contrast, the transgenic expression of membranebound human SCF driven by a ubiquitous promoter results in increased numbers of human mast cells and enhanced HSC engraftment in NSG mice with no reported pathological changes in the murine host 21 . Moreover, newborn NSG mice expressing membranebound human SCF support high levels of human HSC engraftment without the need for X-ray-mediated conditioning 22 . A caveat associated with expressing human factors in immunodeficient mice is that although some murine cytokines do not exert their functions on human cells, many of the human factors cross-react with mouse cells 23 . This could cause unexpected phenotypical changes. For example, the transgenic expression of a factor used to increase the levels of human innate immune cells following human HSC engraftment could upregulate mouse innate immune cells and reduce the levels of human cell engraftment. In addition, even cross-reactive mouse cytokines that can signal to human cells in vitro may have lower in vivo potencies than their corresponding human cytokines.
Additional immunodeficient mouse strains have been developed to minimize the reactivity of human immune cells against host tissue. Such strains include NSG mice that lack MHC class I or MHC class II molecules 24, 25 . These mice were specifically designed to reduce xenogeneic graft-versus-host disease (GVHD), and the transgenic expression of human HLA molecules in these mice permits the development of HLA-restricted human T cells in the absence of H2-restricted human T cells using the human severe combined immuno deficiency (SCID)-repopulating cell SCID (Hu-SRC-SCID) model 25 (TABLE 2).
The current models are appropriate for addressing many questions regarding human immune system development and function, and our understanding of the remaining deficiencies in the models also continues to evolve. These deficiencies are systematically being addressed using genetic and technological approaches to improve human immune system engraftment and function. The continued development of mice expressing human-specific growth factors and HLA moleculescombined with additional approaches to reduce murine H2 expression and decrease host innate immune function -promises to provide models with increased levels of human immune system engraftment and improved functional activity.
Lessons learnt from humanized mice Haematopoiesis. To generate a functional human immune system that contains the multiple cell lineages required for innate and adaptive immunity, immuno deficient Il2rg null mice are engrafted with human HSCs. For many years, it was known that higher numbers of human HSCs engrafted in NOD-scid mice than in immunodeficient CB17, BALB/c and C57BL/6 mice 1 . Of interest was the report that the gene encoding signal regulatory protein-α (SIRPα) in NOD mice has a polymorphism that makes it very similar to the human gene, and that the SIRPα proteins expressed by C57BL/6 and BALB/c mice have much less homology to human SIRPα 26 . Appropriate interaction of SIRPα on host macrophages with human CD47 on engrafted haematopoietic cells is important for haematopoietic cell survival, and therefore expression of human or NOD mouse (human-like) SIRPα is a major determinant for the engraftment and survival of human haematopoietic cells in mice 26 . In BRG mice transgenically expressing human SIRPα, engraftment is increased to the levels achieved in NSG, NOG and NRG mice, indicating that SIRPα is a causal factor in the control of engraftment levels 27 . An NSG mouse strain transgenically expressing human SIRPα is currently under development and will enable the identification of additional strain-specific factors important in human HSC engraftment.
Key insights into the biology of the development of the human immune system from HSCs have been gained using humanized mice. In one study, HSCs derived from human fetal liver, fetal bone marrow and adult bone marrow were used to engraft immuno deficient mice 28 . Fetal liver and fetal bone marrow generated higher numbers of CD4 + CD25 + FOXP3 + regulatory T (T Reg ) cells in the thymus than did adult HSCs. The data suggest a 'layering' null strains. Human cytokines can be expressed transgenically in immunodeficient interleukin-2 (IL-2) receptor γ-chain (Il2rg)-null mouse strains to enhance human haematopoietic cell engraftment and immune system development and function. This has been accomplished for various human cytokines, and models that express others are currently under development. The figure shows the stages of haematopoietic cell development at which these cytokines function. BAFF, B cell-activating factor; DC, dendritic cell; EPO, erythropoietin; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSC, haematopoietic stem cell; M-CSF, macrophage colony-stimulating factor; NK, natural killer; SCF, stem cell factor; THPO, thrombopoietin. ; CMV, cytomegalovirus; FOXP3, forkhead box P3; GM-CSF, granulocyte-macrophage colony-stimulating factor (encoded by CSF2); GVHD, graft-versus-host disease; HSC, haematopoietic stem cell; IL, interleukin; KI, knock-in; M-CSF, macrophage colony-stimulating factor (encoded by CSF1) ; PBL, peripheral blood lymphocyte; PBMC, peripheral blood mononuclear cell; PGK1, phosphoglycerate kinase 1; RBC, red blood cell; SIRPα, signal regulatory protein-α; SCF, stem cell factor (encoded by KITLG); Tg, transgenic; THPO, thrombopoietin.
Graft-versus-host disease (GVHD)
. Tissue damage in a recipient of allogeneic or xenogeneic tissue (usually a bone marrow transplant) that results from the activity of donor cytotoxic T lymphocytes that recognize the tissues of the recipient as foreign. GVHD varies markedly in extent, but it can be life-threatening in severe cases. Damage to the liver, skin and gut mucosa are common clinical manifestations.
Severe combined immunodeficiency
(SCID). Humans or mice with this rare genetic disorder lack functional B and T cells owing to a mutation in a gene that is involved in B cell and T cell development, and consequently they suffer from recurrent infections. Several forms of SCID have been described, including those caused by defects in the IL-2 receptor γ-chain (which is shared by several interleukin receptors), in PRKDC (DNA-dependent protein kinase catalytic subunit), in Janus kinase 3 and in adenosine deaminase.
Central memory T cells
Antigen-experienced T cells that lack immediate effector function but can mediate rapid recall responses. They also rapidly develop the phenotype and function of effector memory T cells after re-stimulation with antigen. Central memory T cells retain the migratory properties of naive T cells and therefore circulate through the secondary lymphoid organs.
Effector memory T cells
Memory T cells that home to peripheral tissues. They are responsible for immediate protection following re-infection.
Germinal centres
Lymphoid structures that arise within follicles after immunization with, or exposure to, a T cell-dependent antigen. They are specialized for facilitating the development of high-affinity, long-lived plasma cells and memory B cells.
of immune system development during ontogeny in humans owing to intrinsic differences in HSC populations, leading to distinct immune systems in fetal versus adult individuals 28 . Another report using humanized mice showed that human myeloid and plasmacytoid dendritic cells can arise from a common precursor that is independent of conventional myeloid and lymphoid haematopoietic pathways 29 . Humanized mice have also been used to analyse the in vivo function of HSCs derived from human induced pluripotent stem (iPS) cells. Although the human iPS cell-derived CD34 + HSCs had the ability to generate both haemato poietic and endothelial cell lineages in vitro, these studies demonstrated preferential differentiation of the CD34 + HSCs into endothelial cells in vivo 30 . Investigations into potential mechanisms of human immune system development and function following the engraftment of HSCs in humanized mice will continue to provide insights into human immune cell biology.
Immune system. One approach for generating humanized mice to study the human immune system is to engraft mature lymphoid cells; this is the case in the human peripheral blood lymphocyte SCID (Hu-PBL-SCID) model. Another option is to engraft HSCs, which has been used in the Hu-SRC-SCID model and the bone marrow, liver, thymus (BLT) model (FIG. 1) .
Studies using Hu-PBL-SCID mice to investigate effector mechanisms in a xenogeneic GVHD system have focused on the efficacy of drugs and T Reg cells in preventing disease 24 . Recent modifications of the Hu-PBL-SCID model have permitted investigation of the infiltration and rejection of human islet, skin and arterial allografts and the cell populations involved in the immune rejection process [31] [32] [33] . The transfer of human T Reg cell populations that were expanded ex vivo prevented the rejection of human skin and arterial grafts in the Hu-PBL-SCID model 34, 35 . These observations demonstrate that human T Reg cells can modulate transplantation rejection and that humanized mice provide both a platform for testing the efficacy of T Reg cells as a cellular therapy and a tool with which to identify the mechanisms underlying the in vivo regulatory activity of these cells.
Of interest was the demonstration that the survival of adoptively transferred antigen-specific central memory T cells is IL-15 dependent, and that these T cells are superior to effector memory T cells in their ability to survive in adoptive recipients, providing guidance for clinical trials of adoptive T cell therapy 36 . Although the rejection of allografts and the development of xenogeneic GVHD have been readily demonstrated in Hu-PBL-SCID mice, antigen-specific activation of T cells has been much harder to document, perhaps owing to the limited engraftment of human antigen-presenting cells (APCs) in this model 24 . To address this, donor-matched human dendritic cells were transferred with PBLs to NSG mice. Following immunization with adenovirus, T cells specific for adenovirus antigens developed 37 , and this model therefore provides an opportunity to test vaccines and investigate the mechanisms underlying antigen-specific T cell immune responses.
One caveat of interpreting results following the engraftment of human effector T cells from PBL populations or other sources in the Hu-PBL-SCID model is the confounding effect of the xenogeneic GVHD response, which is due primarily to human T cell reactivity against mouse MHC molecules 24 . To address this, NSG mice lacking MHC class I and class II molecules (NSG B2m −/− mice and NSG I-A −/− mice, respectively) have been developed, and these mice have less severe xenogeneic GVHD following engraftment with human effector T cells than control NSG mice 24 . Xenogeneic GVHD is further reduced when only purified human CD4 . However, the antibody repertoire in human B cells generated in HSC-engrafted NSG mice is very similar to the repertoire observed in B cells in humans 38, 40 . Also, mouse B cell-activating factor (BAFF; also known as BLyS), which is a crucial B cell differentiation and survival factor, is ineffective on human B cells 41 . The administration of recombinant human BAFF enhances B cell engraftment and survival in the Hu-PBL-SCID model, in which human B cells usually fail to efficiently engraft 41 . Use of recombinant human BAFF during the immunization of humanized mice may support affinity maturation of the antibody response and class-switching from IgM to IgG, and analyses of immunodeficient Il2rg null mice transgenically expressing BAFF are underway. Furthermore, providing both human BAFF and human IL-7 may further enhance the antibody response in humanized mice 41, 42 . Another crucial factor may be the requirement for HLA expression in the mouse host. The engraftment of HLA-DR4 + donor HSCs into NSG Tg(HLA-DR4) or NOG Tg(HLA-DR4) mice permitted the generation of human IgG antibodies following tetanus toxoid vaccination, although antibody levels were still much lower than those observed in immunized humans 43, 44 . In contrast to the difficulties in generating antigenspecific B cell responses in Hu-SRC-SCID and BLT mice, these mice readily generate antigen-specific T cell responses. NSG mice develop a highly diverse T cell repertoire following engraftment with cord blood HSCs 45 , and human CD4 + T cells (including T Reg cells) and CD8 + T cells develop in both the Hu-SRC-SCID and BLT models 7, 46 .
Delayed-type hypersensitivity
A cellular immune response to an antigen that develops over 24-72 hours, involves the infiltration of T cells and monocytes, and is dependent on the production of T helper 1 cell-specific cytokines.
α-galactosylceramide
A synthetic or marine-spongederived glycolipid containing an α-anomeric glycosidic linkage of the galactose residue to the sphingosine base. This lipid, and structurally related ones, potently activates CD1d-restricted natural killer T cells that express the semi-invariant Vα214-Jα18 T cell receptor in mice (or the Vα24-Jα18 equivalent receptor in humans).
Delayed-type hypersensitivity (DTH) responses can be elicited in humanized mice, and an IL-17-specific antibody can block the DTH response to collagen V, suggesting a role for IL-17 in human DTH responses 47 . Moreover, a human T cell-mediated immune response to the superantigen toxic shock syndrome toxin 1 (TSST1) has been demonstrated in BLT mice, permitting the mechanisms underlying this response to be investigated and effective therapies to be tested 48 . The development of functional human T cells in humanized mice can be improved by the administration of recombinant human IL-7 (REFS 5,42). However, insights into the role of IL-7 in human T cell development and function using humanized mice suggest that the timing of administration of human IL-7 is crucial, as exposure to IL-7 before the entrance of T cell progenitors into the thymus impedes rather than enhances human T cell development and function 49 . Of great interest is the use of humanized mice to study the mechanisms underlying human-specific drugs that target T cells. For example, the beneficial effects of teplizumab (a CD3-specific antibody) in type 1 diabetes were shown using humanized mice to be mediated by the induction of gut-tropic T Reg cells, and this observation was then confirmed in patients treated with teplizumab 50 . Human allograft rejection has been studied in the Hu-SRC-SCID model. Using the Hu-SRC-SCID model in BRG mice, islet allograft rejection was not observed, probably owing to the low numbers of human T cells that are generated in these mice 51 . By contrast, using this model in NSG mice, which develop higher numbers of human T cells 7 , islet allograft rejection was observed 52 . A variation combining the Hu-PBL-SCID and Hu-SRC-SCID models has also been used to study human allograft rejection. A Hu-SRC-SCID model generated by the engraftment of mobilized peripheral blood stem cells was used to generate B cells and macrophages in the absence of naive T cells. In this study, CD34-enriched circulating mononuclear cells isolated by leukapheresis following G-CSF-mediated mobilization were injected into the immunodeficient mice along with peripheral blood mononuclear cells (PBMCs) that were autologous to the CD34 + peripheral blood stem cells. This treatment led to the rejection of human artery allograft endothelial cells 33 . Additional studies using this model demonstrated that effector memory CD4 + T cells directly recognize and destroy allogeneic endothelial cells in the tissue graft, and that treatment with a neutralizing antibody specific for human IL-6 enhances the generation of human T Reg cells and prevents rejection 53 . Humanized mice can also be used to study cells of the innate immune system. HSC-engrafted mice can generate human NK cells 1 ; however, the ability of these cells to kill targets is not robust. Pre-activation of the human NK cells or trans-presentation of recombinant human IL-15 enhances the development of these cells in humanized mice, and they begin to acquire cytotoxic activity 54, 55 . However, the transgenic expression of human HLA molecules by the mouse host will be required to allow complete NK cell 'licensing' and thereby permit the development of fully functional human NK cells. An additional component of the human immune system that could not be studied in rodents until recently owing to species-specific differences is the CD1 antigen-presenting system. Using NSG BLT mice, it was shown that a functional human CD1-dependent cellular compartment can develop in these mice 56 . This was confirmed by CD1d tetramer staining of human invariant natural killer T (iNKT) cells from these mice, and by demonstrations of IFNγ secretion by the CD1-restricted iNKT cells and of rapid IFNγ and IL-4 production following the injection of α-galactosylceramide 56 . This now permits, for the first time, the investigation of the human CD1 system in a small-animal model.
Infectious diseases
A major experimental use of humanized mice over the past few years has been for the study of human infectious agents (TABLE 4 ). An example of the utility of Hu-SRC-SCID mice for infectious disease experiments was the study of Salmonella enterica subsp. enterica serovar Typhi infection [57] [58] [59] . S. Typhi is highly adapted to humans and fails to cause progressive infection in mice. Much of the current understanding of the pathogenesis of S. enterica infection has resulted from studies of S. Typhimurium in mice, but many differences exist between S. Typhi and S. Typhimurium. In a study using NSG Hu-SRC-SCID mice infected with S. Typhi, granulomatous inflammation with mononuclear cell infiltration was observed in the spleen, which mimics the human pathology, and the infection rapidly induced fatality. Moreover, the screening of transposon pools in infected NSG Hu-SRC-SCID mice revealed previously unrecognized S. enterica virulence determinants 57 . In additional studies using the Hu-SRC-SCID model, prolonged survival following S. Typhi infection was observed and was associated with neurological symptoms in BRG mice 59 and with human innate and adaptive immune responses in BRG mice 58 . These differences in pathogenesis and lethality following S. Typhi infection highlight the differences in the different strains of humanized mice (NSG versus BRG mice), with each having its own advantages and constraints.
A NOG HSC-engrafted model of Epstein-Barr virus (EBV) infection has been described that closely mimics the pathological effects observed following the infection of humans with EBV. Indeed, the disease generated in the model resembles a syndrome termed haemophagocytic lymphohistiocytosis, a rare but devastating disorder in EBV-infected individuals 60 . The availability of HLA-A2-transgenic immunodeficient IL2rg null mice has permitted the extension of the use of infection models to the study of HLA-A2-restricted human CD8 + T cell responses to infectious agents [61] [62] [63] . Infection of HSC-engrafted immunodeficient NSG HLA-A2-transgenic mice with EBV led to the development of HLA-A2-restricted human CD8 + T cell responses and protective CD4 + and CD8 + T cell-mediated immunity 61, 62 . A humanized mouse model of EBV infection is particularly important, as pre-symptomatic stages of EBV infection in humans are largely unexplored but can now be investigated in humanized mice. HLA-A2-restricted human T cell responses have also been observed following dengue virus infection in NSG HLA-A2-transgenic mice engrafted with HSCs and in BLT mice 63 . Infected humans can develop severe capillary leakage syndrome (dengue haemorrhagic fever) following a second infection with a different dengue virus serotype, although little is known about the immune response or mechanisms through which this occurs 64 . Humanized mice may become a useful model for studying the role of prior immunity to dengue virus in contributing to this disease 64 . One of the greatest impacts of humanized mice has been in the field of HIV research. Studies of HIV infection in humanized mice have utilized all four models of immune system engraftment (Hu-PBL-SCID, Hu-SRC-SCID, SCID-Hu and BLT) and have been extensively reviewed elsewhere [65] [66] [67] [68] ; therefore, only key recent advances are discussed here. Numerous studies have tested HIV therapeutic interventions that limit viral replication and CD4 + T cell depletion. These therapeutic interventions include systemic antiretroviral therapy 69 , the systemic delivery of HIV-neutralizing antibodies 70, 71 , the transplantation of genetically modified HSCs 72, 73 , and novel approaches for delivering small inhibitory RNAs specific for either cellular or viral targets [74] [75] [76] . In addition, recent studies using antiretroviral drugs to suppress viraemia have demonstrated that HIV latency in CD4 + T cells occurs in humanized mice, highlighting the value of these models for evaluating HIV eradication strategies [77] [78] [79] . In a related study, Hu-SRC-SCID mice were used to examine the potential of HSCs to serve as a reservoir of latent HIV 80 . In the BLT model, robust human mucosal immune systems render these animals susceptible to oral, rectal and vaginal HIV transmission [81] [82] [83] . The susceptibility of BLT mice to mucosal HIV transmission permits the evaluation of HIV prevention strategies using topically or systemically applied viral inhibitors 76, 81, 82 . Importantly, the infection of BLT mice results in rapid systemic dissemination of the virus and the depletion of peripheral CD4 + T cells (including gastrointestinal CD4 + T cells), which is similar to what is observed in humans 81 .
Together, these studies demonstrate the broad applicability of humanized mice in preclinical HIV research.
Both the function and HIV-associated dysfunction of the human immune system have been described in HIV-infected humanized mice. In BLT mice, the production of low levels of HIV-specific antibody was detected by 8 weeks post-infection 84 , and by 16 weeks all of the infected mice were producing human HIV-specific immunoglobulins 85 . Furthermore, HIV epitope-restricted cytotoxic T lymphocyte (CTL) responses were detected in HIV-infected BLT mice 85 . Additional evidence of CTL function against HIV in humanized mice includes the finding that depletion of human CD8 + T cells accelerates HIV-induced immunopathology, suggesting a role for these cells in controlling infection 86 . An extensive sequencing analysis showed that selective pressure from the immune system can drive the evolution of the HIV env gene in Hu-SRC-SCID mice 87 , and functional innate immune responses against HIV mediated by the antiretroviral cytidine deaminase APOBEC3 have been demonstrated 88 . Immune dysfunction in HIV disease is, in part, characterized by abnormal immune activation 89 , and a similar activated T cell phenotype has been recently described in BLT mice 90 . Moreover, Hu-SRC-SCID mice have been used to demonstrate that HIV infection activates and impairs the function of plasmacytoid dendritic cells 91 . Finally, the influx of human macrophages into the brain of Hu-SRC-SCID mice exhibiting progressive HIV infection was linked with viral neuropathogenesis 92, 93 . These studies reveal functional human immune responses in humanized mice and show that known and new HIV-induced immune dysfunctions can be studied in these models. ; PBL, peripheral blood lymphocyte; RBC, red blood cell; SCID-Hu, SCID human (fetal liver and thymus).
Systemic lupus erythematosus
(SLE). An autoimmune disease in which autoantibodies specific for DNA, RNA or proteins associated with nucleic acids form immune complexes. These complexes damage small blood vessels, especially in the kidneys. Patients with SLE generally have abnormal B and T cell function.
Lymphoid tissue inducer cell
A cell that is present in developing lymph nodes, Peyer's patches and nasopharynx-associated lymphoid tissue (NALT). Lymphoid tissue inducer cells are required for the development of these lymphoid organs. The inductive capacity of these cells for the generation of Peyer's patches and NALT has been shown by adoptive transfer, and it is generally assumed that they have a similar function in the formation of lymph nodes.
Autoimmunity
There are only a few reports of successful recapitulation of autoimmune diseases in humanized mice. In one study using the Hu-PBL-SCID model engrafted with PBLs from individuals with systemic lupus erythematosus (SLE), the mice developed microthrombi, and B and T cells infiltrated the glomeruli, which are features of SLE 94 . Another report showed that islet-associated T cells could be isolated from NSG Tg(HLA-A2) mice that had received HLA-A2-matched PBLs from individuals with type 1 diabetes, suggesting that this might provide a model for studying diabetogenic T cells 95 . In a study using the Hu-SRC-SCID engraftment model, bone marrow-derived HSCs from patients with osteoarthritis were transferred into NOD-scid mice that had been depleted of NK cells (using a CD122-specific antibody), and these mice developed synovial inflammation following intra-articular injection of Chlamydia trachomatis to induce arthritis 96 .
To date, studies of the immunological mechanisms of autoimmunity have yet to be performed using these models. However, as the next generation of humanized mice becomes available, modelling of autoimmune disorders and investigation into the immunological mechanisms underlying autoimmune diseases will follow.
Tumour immunology
Humanized mice have permitted new types of human tumours to be grown and studied in vivo 1 . Although not discussed in this article, these new models have been used to characterize cancer stem cells and other facets of tumour biology 97, 98 . Reports are now appearing on features of the human antitumour immune response. The transplantation of primary lung tumours into humanized mice revealed the existence of tumour-infiltrating effector memory T cells that could be activated by the administration of human IL-12 (REF. 99 ). Primary human epithelial ovarian tumours engrafted in NSG mice also contain human T cells, and efforts are underway to activate the intratumour T cells for the induction of immune responses against ovarian tumours 100 . Humanized mice have also been used to study antitumour therapies. CD47 is expressed on most human solid tumours, and the administration of an antibody specific for human CD47 to NSG mice bearing human tumours leads to the phagocytosis and elimination of tumour cells. This demonstrates that tumour-engrafted NSG mice can be used to evaluate antibody-mediated cancer therapies 101 . In BLT mice, the engraftment of HSCs transduced with MHC class I-restricted T cell receptors specific for tumour antigens has been shown to promote the control of human melanomas 102 . This model will be important for optimizing cellular adoptive therapies for the treatment of melanomas. In addition, the efficacy of adoptive transfer of human T cells genetically engineered to express melanoma antigen-specific T cell receptors has been evaluated in NOG mice 103 . Finally, in a novel approach, newborn NSG mice were co-engrafted with human HSCs and human breast cancer cells. The tumours grew in the presence of the immune system, and the generation of tumour-specific T cells was observed, as well as NK cell accumulation at the tumour site 104 . Understanding the resistance of the tumour to the engrafted immune system and how to modulate the immune system to overcome this resistance will provide new approaches for cancer immunotherapy.
Future promise and remaining challenges
The new models that have been described and used to study human immunity are only the beginning of the next generation of humanized mice that will soon be available. Remaining challenges are to generate new strains of mice in which there is further enhancement of the human immune system with reduced mouse innate immune responses 1, 2 (TABLE 5) .
A crucial remaining issue is the limited development of lymph nodes in immunodeficient Il2rg null mice. Although mesenteric lymph nodes develop, other peripheral lymph nodes are small with little to no lymphoid organization 105 . Current approaches to address this problem include the administration of human IL-7, which is crucial for the neonatal maturation of lymph nodes 106 , and the provision of agonistic antibodies specific for the human lymphotoxin-β receptor during a crucial early maturation step in lymph node development 107 . One of the cell populations that are deficient in Il2rg null mice is the lymphoid tissue inducer cell population, which is required for the formation of lymph nodes and gutassociated lymphoid tissue. Efforts to identify approaches to enhance the development of these cells are continuing.
Another limitation is being addressed through the generation of immunodeficient Il2rg null HLA-transgenic mice that express many of the common HLA class I superfamilies 108 . For the study of autoimmunity, a panel of HLA class II-transgenic NSG mice are being developed. These new models will facilitate investigations of type 1 diabetes, multiple sclerosis and rheumatoid arthritis -autoimmune disorders strongly associated with specific HLA class II alleles. For the study of human NK cells, NSG HLA-transgenic mice expressing HLA-B27 or HLA-Cw*0304, which are important in NK cell licensing, are under investigation. The use of HLA-transgenic mice co-expressing BAFF and/or IL-7 may increase B and T cell function, respectively, and enhance immune responses. Overcoming poor adaptive humoral immune responses in humanized mice will result in more effective models for vaccine testing.
Additional modifications are needed for studies of infectious agents that require circulating human red blood cells or resident hepatocytes as part of their life cycle. Such agents include Plasmodium falciparum, which has obligate stages in both hepatocytes and red blood cells. Mouse macrophages are a significant impediment to the survival of human red blood cells in NSG mice, and the depletion of mouse macrophages allows enhanced development and survival of peripheral human red blood cells in BLT mice 109 . Similarly, the study of hepatitis B and C virus infections in the presence of an immune system requires the presence of both human hepatocytes and human HSCs in the humanized mouse. One approach to achieve this has been to engraft human fetal liver hepatocytes and HSCs into an immunodeficient recipient that has additional genetic modifications that induce host liver cell damage. Both human liver tissue and a human immune system developed in this model, and the mice supported infection with hepatitis C virus 110 . For proper immune function, appropriate trafficking of human immune cells to non-lymphoid tissues is required. Owing to species-specific differences in adhesion mol ecules and the potential incompatibilities of receptor-ligand pairs, human lymphocyte homing may not occur properly in immunodeficient mice. For example, there are known species-specific differences between mice and humans in lymphocyte function-associated antigen 1 (LFA1; also known as αLβ2 integrin) and intercellular adhesion molecule 1 (ICAM1). Mouse ICAM1 can bind to human LFA1, but mouse LFA1 does not bind to human ICAM1 (REF. 111) .
One of the final obstacles in establishing a full human chimaera is the inability of several human haematopoietic cell lineages, including granulocytes, platelets and red blood cells, to circulate and traffic appropriately in the murine host. When the murine host is conditioned sufficiently to replace essentially all of the murine bone marrow with human haematopoietic cells, the mice die, probably owing to severe anaemia and/or greatly reduced levels of circulating platelets and granulocytes 21 . Although pro genitors of human red blood cells, platelets and granulocytes are detected in the bone marrow, few of these cell populations are found in the circulation, probably as a result of their removal in the circulation by murine macrophages 112 . Administration of G-CSF to NSG mice engrafted with human cord blood HSCs was recently reported to enhance the mobilization of mature human myeloid cells into the circulation 113 .
Conclusion and perspective
The diversity of humanized mouse strains, the differences in the approaches for the engraftment of human cells and tissues, and the various technological approaches being used to generate the next generation of immuno deficient Il2rg null mice lead to the key caveat in the use of humanized mice for the study of human immunology. Experiments using humanized mice, or any animal model system, need to be designed to address a mechanistic question rather than attempting to fully recapitulate the human biological process or pathology. With this caveat in mind, humanized mice are becoming increasingly important tools in translational biomedical research, permitting insights into human haematopoiesis, innate and adaptive immunity, autoimmunity, infectious disease and cancer immunology. 
